Feasibility of aspirin and/or vitamin D3 for men with prostate cancer on active surveillance with Prolaris® testing.
Eoin DinneenGregory L ShawRoseann KealyPanos AlexandrisKier FinneganKimberley ChuNadia HaidarSara Santos-VidalSakunthala KudahettiCaroline M MooreAlistair D R GreyDaniel M BerneyAnju SahdevPaul J CathcartR Timothy D OliverPrabhakar RajanJack Cuzicknull nullJack CuzickSanjeev MadaanJhumur PatiAbdul M ChowdhuryBrian R P BirchTimothy J DudderidgeCaroline M MooreAlistair D R GreyGregory L ShawKieran P JeffersonHoward G KynastonPrabhakar RajanJames S A GreenPaul J CathcartDaniel M BerneyThomas PowlesR Timothy D OliverAnju SahdevRoseann KealyVictoria KempPanos AlexandrisKier FinneganKimberly ChuPublished in: BJUI compass (2022)
Recruitment of AS PCa patients into a multi-centre multi-arm placebo-controlled RCT of minimally-toxic adjunctive oral drug treatments with molecular biomarker profiling is acceptable and safe. A larger phase III study is needed to determine optimal agents, intervention efficacy, and outcome-associated biomarkers.
Keyphrases
- phase iii
- prostate cancer
- placebo controlled
- end stage renal disease
- double blind
- clinical trial
- open label
- randomized controlled trial
- ejection fraction
- chronic kidney disease
- newly diagnosed
- phase ii
- radical prostatectomy
- low dose
- peritoneal dialysis
- study protocol
- emergency department
- prognostic factors
- single cell
- atrial fibrillation
- coronary artery disease
- single molecule
- middle aged
- electronic health record